AAPL343.57+1.57 (+0.46%) ▲|ABBV285.36+1.96 (+0.69%) ▲|ABT104.42-0.27 (-0.25%) ▼|ACN225.86+0.94 (+0.42%) ▲|ADBE244.87-6.80 (-2.70%) ▼|AMAT416.92-13.10 (-3.05%) ▼|AMD534.70-27.53 (-4.90%) ▼|AMGN433.20-0.84 (-0.19%) ▼|AMT185.01+3.65 (+2.01%) ▲|AMZN249.28-5.48 (-2.15%) ▼|AVGO330.80-13.53 (-3.93%) ▼|AXP313.09-0.79 (-0.25%) ▼|BA188.42-0.31 (-0.17%) ▼|BAC51.50-0.21 (-0.40%) ▼|BKNG162.76-3.04 (-1.83%) ▼|BLK1,126.59+5.81 (+0.52%) ▲|BMY60.55-0.02 (-0.03%) ▼|BNY142.52+0.43 (+0.30%) ▲|BRK-B529.35+3.67 (+0.70%) ▲|C124.00+0.79 (+0.64%) ▲|CAT736.42+0.78 (+0.11%) ▲|CL93.16+0.49 (+0.53%) ▲|CMCSA21.96+0.19 (+0.85%) ▲|COF200.92+2.06 (+1.04%) ▲|COP146.19+4.46 (+3.15%) ▲|COST991.40+13.39 (+1.37%) ▲|CRM240.54-6.20 (-2.51%) ▼|CSCO107.59-2.26 (-2.06%) ▼|CVS92.09-0.49 (-0.53%) ▼|CVX224.33+5.01 (+2.28%) ▲|DE640.03-10.64 (-1.64%) ▼|DHR229.45-2.05 (-0.89%) ▼|DIS110.26-0.43 (-0.38%) ▼|DUK121.17+2.29 (+1.93%) ▲|EMR160.12-2.04 (-1.26%) ▼|FDX292.83-2.71 (-0.92%) ▼|GD342.83+5.80 (+1.72%) ▲|GE315.38+3.38 (+1.08%) ▲|GEV927.49+1.05 (+0.11%) ▲|GILD156.01-1.36 (-0.86%) ▼|GM83.83+0.17 (+0.20%) ▲|GOOG337.34-7.58 (-2.20%) ▼|GOOGL341.03-8.20 (-2.35%) ▼|GS880.60-10.68 (-1.20%) ▼|HD310.27+2.03 (+0.66%) ▲|HON211.75+1.25 (+0.59%) ▲|IBM231.78-2.34 (-1.00%) ▼|INTC90.65-4.73 (-4.95%) ▼|INTU322.89-7.29 (-2.21%) ▼|ISRG428.39+0.53 (+0.12%) ▲|JNJ255.38+2.10 (+0.83%) ▲|JPM338.55+3.02 (+0.90%) ▲|KO93.02+1.02 (+1.10%) ▲|LIN497.38+4.16 (+0.84%) ▲|LLY1,257.14+5.53 (+0.44%) ▲|LMT548.13+15.49 (+2.91%) ▲|LOW196.90+1.18 (+0.60%) ▲|LRCX266.89-10.57 (-3.81%) ▼|MA614.59-1.74 (-0.28%) ▼|MCD243.11+0.61 (+0.25%) ▲|MDLZ63.87+0.84 (+1.33%) ▲|MDT94.45-1.00 (-1.05%) ▼|META707.26-29.47 (-4.00%) ▼|MMM164.09-1.24 (-0.75%) ▼|MO74.94+1.10 (+1.48%) ▲|MRK146.53+1.34 (+0.92%) ▲|MS180.67-1.43 (-0.79%) ▼|MSFT527.30-12.14 (-2.25%) ▼|MU892.14-39.10 (-4.20%) ▼|NEE79.81+0.85 (+1.08%) ▲|NFLX70.24-2.38 (-3.27%) ▼|NKE36.97-0.17 (-0.46%) ▼|NOW140.95-7.63 (-5.13%) ▼|NVDA214.95-2.29 (-1.05%) ▼|ORCL128.50-5.97 (-4.44%) ▼|PEP130.83+2.45 (+1.91%) ▲|PFE29.52+0.08 (+0.26%) ▲|PG158.47+1.39 (+0.88%) ▲|PLTR186.45-14.06 (-7.01%) ▼|PM204.54+4.64 (+2.32%) ▲|QCOM172.89-5.52 (-3.09%) ▼|RTX192.69+5.74 (+3.07%) ▲|SBUX96.92+0.04 (+0.04%) ▲|SCHW91.81-2.35 (-2.50%) ▼|SO90.69+1.51 (+1.69%) ▲|SPG204.68+1.29 (+0.63%) ▲|T23.57+0.07 (+0.28%) ▲|TMO687.51-8.98 (-1.29%) ▼|TMUS158.81+1.78 (+1.13%) ▲|TSLA352.27-10.17 (-2.81%) ▼|TXN278.65-0.47 (-0.17%) ▼|UBER70.00-1.28 (-1.79%) ▼|UNH402.21-4.46 (-1.10%) ▼|UNP287.50-1.21 (-0.42%) ▼|UPS96.89-0.95 (-0.97%) ▼|USB58.43+1.04 (+1.80%) ▲|V401.07+1.32 (+0.33%) ▲|VZ44.84+0.44 (+0.99%) ▲|WFC83.59+0.84 (+1.02%) ▲|WMT118.73+0.86 (+0.73%) ▲|XOM178.13+3.45 (+1.98%) ▲|AAPL343.57+1.57 (+0.46%) ▲|ABBV285.36+1.96 (+0.69%) ▲|ABT104.42-0.27 (-0.25%) ▼|ACN225.86+0.94 (+0.42%) ▲|ADBE244.87-6.80 (-2.70%) ▼|AMAT416.92-13.10 (-3.05%) ▼|AMD534.70-27.53 (-4.90%) ▼|AMGN433.20-0.84 (-0.19%) ▼|AMT185.01+3.65 (+2.01%) ▲|AMZN249.28-5.48 (-2.15%) ▼|AVGO330.80-13.53 (-3.93%) ▼|AXP313.09-0.79 (-0.25%) ▼|BA188.42-0.31 (-0.17%) ▼|BAC51.50-0.21 (-0.40%) ▼|BKNG162.76-3.04 (-1.83%) ▼|BLK1,126.59+5.81 (+0.52%) ▲|BMY60.55-0.02 (-0.03%) ▼|BNY142.52+0.43 (+0.30%) ▲|BRK-B529.35+3.67 (+0.70%) ▲|C124.00+0.79 (+0.64%) ▲|CAT736.42+0.78 (+0.11%) ▲|CL93.16+0.49 (+0.53%) ▲|CMCSA21.96+0.19 (+0.85%) ▲|COF200.92+2.06 (+1.04%) ▲|COP146.19+4.46 (+3.15%) ▲|COST991.40+13.39 (+1.37%) ▲|CRM240.54-6.20 (-2.51%) ▼|CSCO107.59-2.26 (-2.06%) ▼|CVS92.09-0.49 (-0.53%) ▼|CVX224.33+5.01 (+2.28%) ▲|DE640.03-10.64 (-1.64%) ▼|DHR229.45-2.05 (-0.89%) ▼|DIS110.26-0.43 (-0.38%) ▼|DUK121.17+2.29 (+1.93%) ▲|EMR160.12-2.04 (-1.26%) ▼|FDX292.83-2.71 (-0.92%) ▼|GD342.83+5.80 (+1.72%) ▲|GE315.38+3.38 (+1.08%) ▲|GEV927.49+1.05 (+0.11%) ▲|GILD156.01-1.36 (-0.86%) ▼|GM83.83+0.17 (+0.20%) ▲|GOOG337.34-7.58 (-2.20%) ▼|GOOGL341.03-8.20 (-2.35%) ▼|GS880.60-10.68 (-1.20%) ▼|HD310.27+2.03 (+0.66%) ▲|HON211.75+1.25 (+0.59%) ▲|IBM231.78-2.34 (-1.00%) ▼|INTC90.65-4.73 (-4.95%) ▼|INTU322.89-7.29 (-2.21%) ▼|ISRG428.39+0.53 (+0.12%) ▲|JNJ255.38+2.10 (+0.83%) ▲|JPM338.55+3.02 (+0.90%) ▲|KO93.02+1.02 (+1.10%) ▲|LIN497.38+4.16 (+0.84%) ▲|LLY1,257.14+5.53 (+0.44%) ▲|LMT548.13+15.49 (+2.91%) ▲|LOW196.90+1.18 (+0.60%) ▲|LRCX266.89-10.57 (-3.81%) ▼|MA614.59-1.74 (-0.28%) ▼|MCD243.11+0.61 (+0.25%) ▲|MDLZ63.87+0.84 (+1.33%) ▲|MDT94.45-1.00 (-1.05%) ▼|META707.26-29.47 (-4.00%) ▼|MMM164.09-1.24 (-0.75%) ▼|MO74.94+1.10 (+1.48%) ▲|MRK146.53+1.34 (+0.92%) ▲|MS180.67-1.43 (-0.79%) ▼|MSFT527.30-12.14 (-2.25%) ▼|MU892.14-39.10 (-4.20%) ▼|NEE79.81+0.85 (+1.08%) ▲|NFLX70.24-2.38 (-3.27%) ▼|NKE36.97-0.17 (-0.46%) ▼|NOW140.95-7.63 (-5.13%) ▼|NVDA214.95-2.29 (-1.05%) ▼|ORCL128.50-5.97 (-4.44%) ▼|PEP130.83+2.45 (+1.91%) ▲|PFE29.52+0.08 (+0.26%) ▲|PG158.47+1.39 (+0.88%) ▲|PLTR186.45-14.06 (-7.01%) ▼|PM204.54+4.64 (+2.32%) ▲|QCOM172.89-5.52 (-3.09%) ▼|RTX192.69+5.74 (+3.07%) ▲|SBUX96.92+0.04 (+0.04%) ▲|SCHW91.81-2.35 (-2.50%) ▼|SO90.69+1.51 (+1.69%) ▲|SPG204.68+1.29 (+0.63%) ▲|T23.57+0.07 (+0.28%) ▲|TMO687.51-8.98 (-1.29%) ▼|TMUS158.81+1.78 (+1.13%) ▲|TSLA352.27-10.17 (-2.81%) ▼|TXN278.65-0.47 (-0.17%) ▼|UBER70.00-1.28 (-1.79%) ▼|UNH402.21-4.46 (-1.10%) ▼|UNP287.50-1.21 (-0.42%) ▼|UPS96.89-0.95 (-0.97%) ▼|USB58.43+1.04 (+1.80%) ▲|V401.07+1.32 (+0.33%) ▲|VZ44.84+0.44 (+0.99%) ▲|WFC83.59+0.84 (+1.02%) ▲|WMT118.73+0.86 (+0.73%) ▲|XOM178.13+3.45 (+1.98%) ▲|
21.2 C
New York
Friday, October 16, 2026

Tag: prescription

newssourceFORcompanycontentinformation1releasesmarket

Modesto Residents Will Gain Access to More Affordable Homes Due to $4 Million Health Net Investment

Morris Village development will expand access to long-term housing stability for families and individuals in Stanislaus CountySACRAMENTO, Calif., June 18, 2026 /PRNewswire-HISPANIC PR WIRE/...

Boston Business Journal names Interra Health to 2026 Best Places to Work List

The Boston Business Journal has named Interra Health to its 2026 Best Places to Work list.

Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026)

– Lorundrostat was associated with significant reductions in heart failure risk biomarkers in a proteomic analysis of data from participants with uncontrolled hypertension –

HorseWood & HorseBoost [Exclusive Report 2026] The Horse Gelatin Trick Male Enhancement Or Why Talking About Natural Vitality Supplement Horse Boost?

Discover the truth behind HorseWood & HorseBoost in this 2026 exclusive report. Learn how the Horse Gelatin Trick works, what ingredients are included, and whether this natural vitality supplement can support male performance, stamina, and confidence. 
Discover the truth behind HorseWood & HorseBoost in this 2026 exclusive report. Learn how the Horse Gelatin Trick works, what ingredients are included, and whether this natural vitality supplement can support male performance, stamina, and confidence.

Lilly’s Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited regimen in people with...

BRUIN CLL-322 is the first Phase 3 study to demonstrate superiority over a venetoclax-containing control arm in CLL, and, with the majority of patients...

ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Zoetis Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ZTS

NEW YORK, June 13, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Zoetis Inc. (NYSE: ZTS) between January 14, 2025 and May 6, 2026, inclusive (the “Class Period”), of the important July 27, 2026 lead plaintiff deadline.

HeroMD 4-MAX Claims Evaluated: Why Men Searching “Most Effective 4-in-1 Erectile Dysfunction Formula” Are Comparing SURGE, PRIME and The HERO System Explained

HeroMD 4-MAX scam or legit? Compounded 4-in-1 sublingual ED formula with 10-min onset and 36-hr window reviewed.

Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type...

SAN DIEGO, June 12, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced the completion of its rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for tinlarebant. Tinlarebant is an investigational, once-daily oral therapy for the treatment of Stargardt disease type 1 (STGD1), a rare, inherited retinal disease caused by mutations in the ABCA4 gene that leads to progressive and irreversible vision loss. STGD1 affects an estimated 53,000 people in the U.S. alone, and there are currently no approved treatment options for the disease.

HorseWood Claims Evaluated: The Horse Gelatin Trick for Natural Male Enhancement Support

Horsewood supplement evaluated: 7-herb botanical male vitality formula, NCCIH research context, and 60-day money-back guarantee.

BRC Therapeutics Appoints Ron Eastman to Board of Directors

Veteran Pharma Executive and Healthcare Investor Brings More Than 40 Years of Drug Development, Operations and Investment ExperienceMONTEREY, Calif., June 12, 2026 /PRNewswire/ -- BRC...

HUTCHMED Highlights Sovleplenib ESLIM-02 Phase III Data in Warm Antibody Autoimmune Hemolytic Anemia Presented at EHA 2026 Congress

— Sovleplenib demonstrated rapid and durable hemoglobin response with favorable safety profile —

Novo Nordisk: Wegovy® pill (semaglutide tablets) becomes first daily GLP-1 weight-loss pill approved in the UK

Novo Nordisk's Wegovy® pill has been approved in the UK as an adjunct to a reduced-calorie diet and increased physical activity for adults

60 Degrees Pharmaceuticals Signs Exclusive Patent License Agreement with Florida State University for Non-Prescription Use of Australian Chestnut Extract as a Botanical Supplement

60 Degrees Pharma licensed FSU technology for Australian Chestnut Extract production and plans FDA discussions before refiling its NDIN.

IMAAVY® (nipocalimab-aahu) demonstrates durable hemoglobin response and rapid onset of effect in pivotal Phase 2/3 study in warm autoimmune hemolytic anemia (wAIHA), an autoantibody-driven...

Patients in the IMAAVY 30 mg/kg treatment groupa achieved statistically significant durable hemoglobin responseb, with mean hemoglobin improvement of at least 1 g/dL as...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsPrescription

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers